Personalized Management and Timing of Thymectomy in Juvenile Myasthenia Gravis: Insights from Routine Clinical Scale Use in a Single-Center Retrospective Cohort—A Case Series
Authors:
- Gulten OzturkGOGulten Ozturk
- Olcay UnverOUOlcay Unver
- Elif Acar ArslanEAElif Acar Arslan
- Nezih Onur ErmerakNENezih Onur Ermerak
- Bilgihan BıkmazerBBBilgihan Bıkmazer
- Hakkı AkbeyazHAHakkı Akbeyaz
- Burcu KarakayaliBKBurcu Karakayali
- Sermin Aksoy OzcanSOSermin Aksoy Ozcan
- Gulcan AkyuzGAGulcan Akyuz
- Pınar ErgenekonPEPınar Ergenekon
- Yasemin GokdemirYGYasemin Gokdemir
- Ela Erdem EralpEEEla Erdem Eralp
Open Access
Abstract
Introduction: Juvenile myasthenia gravis (JMG) is a rare autoimmune disorder with a variable clinical course and limited pediatric-specific treatment guidelines. Objective clinical scales, such as the Quantitative Myasthenia Gravis (QMG) Score and the Pediatric Myasthenia Gravis Quality of Life 15 (PM-QOL15), may support individualized management, but their role in routine practice remains underexplored. Methods: We retrospectively reviewed 10 seropositive JMG patients followed at a single tertiary neuromuscular clinic between 2014 and 2024. All patients underwent a systematic assessment with QMG at each visit, while PM-QOL15 was administered at the final visit. Clinical data, comorbidities, antibody status, treatment modalities, and outcomes were analyzed. Associations between treatment strategies, comorbidities, and scale scores were explored using appropriate statistical methods. Results: Seven patients (70%) underwent thymectomy, resulting in a reduction in mean QMG scores from 7.7 to 2.4, though residual relapses were observed. Chronic intravenous immunoglobulin (IVIG) therapy, administered to 70% of patients, did not significantly reduce relapse rates or steroid exposure and was associated with higher QMG scores in the second year, suggesting use in more severe phenotypes rather than therapeutic efficacy. Prolonged corticosteroid therapy did not improve remission time or relapse frequency and was complicated by major adverse effects in two patients. Timing of azathioprine initiation showed no significant correlation with relapse frequency. PM-QOL15 correlated strongly with mean QMG (r = 0.88, p < 0.001), reflecting cumulative disease burden. Patients with comorbidities required longer stabilization, although differences were not statistically significant. Conclusions: The routine integration of QMG and PM-QOL15 into follow-up may facilitate the earlier recognition of subclinical deterioration, provide objective measures of treatment response, and guide personalized management in JMG. Thymectomy showed benefit in selected patients, while the long-term roles of IVIG and corticosteroids remain uncertain. Larger multicenter prospective studies are warranted to confirm these findings and refine evidence-based strategies for pediatric JMG.Keywords
This publication has 22 references indexed in Scilit:
- Myasthenia gravis in 2025: five new things and four hopes for the futureJournal of Neurology, 2025
- Targeted Treatments for Myasthenia Gravis in Children and AdolescentsPediatric Drugs, 2024
- Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patientsNeurological Sciences, 2024
- Effectiveness of thymectomy in juvenile myasthenia gravis and clinical characteristics associated with better outcomesNeuromuscular Disorders, 2021
- Developing outcome measures of disease activity in pediatric myastheniaMuscle & Nerve, 2021
- 242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1–3 March 2019Neuromuscular Disorders, 2020
- The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic reviewPediatric Surgery International, 2017
- International clinimetric evaluation of the MG‐QOL15, resulting in slight revision and subsequent validation of the MG‐QOL15rMuscle & Nerve, 2016
- Intravenous immunoglobulin maintenance treatment in myasthenia gravis: A randomized, controlled trial sample size simulationMuscle & Nerve, 2014
- Juvenile myasthenia gravisMuscle & Nerve, 2009